Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix.

The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.

A membrane for skin comprising a plurality of randomly oriented core-shell nanofibers is provided in the present invention, where each of said core-shell nanofibers comprises at least an active-ingredient-loaded polymeric core and a non-polymeric shell consisting of active ingredients only surrounding the core. Related fabrication method of said membrane is also provided in the present invention.

The present invention relates to free-form structures made by additive manufacturing, and methods for the manufacture thereof. The rigid free-form structures comprise a lattice structure which is impregnated by a polymeric or other material. The rigid free-form structures may be used in wound treatment, e.g., as a facial mask.

The invention relates to a patch for administering an active substance to the skin of a subject. The present patches simplify manufacture and improve reproducibility of results, facilitate, and enhance the consistency of application of the patches to a subject, and demonstrate improved initial and long-term adhesion with reduced risk of premature detachment.

A method of treating microbial infections that entails producing a space over the infected site by covering such site with an impermeable material and then filling such space with an antimicrobial material (in the form of a solution, cream, gel, colloid, etc) comprising an efflux pump inhibitor soluble in a non-polar solvent is provided. The antimicrobial material can also be applied in multiple other ways such as a cream or released from a band-aid or gauze. Such treatment method may also be used with newly discovered antibiotics.

Disclosed are a microneedle patch including a first hydrogel layer containing a mussel adhesive protein and hyaluronic acid, and a second hydrogel layer containing silk fibroin, and a preparation method thereof. The microneedle patch according to the present disclosure has excellent tissue adhesion, biocompatibility, and biodegradability, and is used for transdermal drug delivery to promote wound regeneration.

Since treatment effects of conventional external preparations were not satisfactory, it is aimed to provide a novel external preparation that is excellent in drug permeability to nail, capable of fully exhibiting effects of an antifungal drug, and effective for treatments of diseases such as nail mycosis and nail candidiasis, particularly, treatments for nail tinea. The external preparation of this invention is a pharmaceutical composition for nail characterized by containing an antifungal drug, alkylpyrrolidone or a derivative thereof, and a crosslinking hydrogel.

A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix.

The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.

Since treatment effects of conventional external preparations were not satisfactory, it is aimed to provide a novel external preparation that is excellent in drug permeability to nail, capable of fully exhibiting effects of an antifungal drug, and effective for treatments of diseases such as nail mycosis and nail candidiasis, particularly, treatments for nail tinea. The external preparation of this invention is a pharmaceutical composition for nail characterized by containing an antifungal drug, alkylpyrrolidone or a derivative thereof, and a crosslinking hydrogel.